UNIVERSITYOF BIRMINGHAM

University of Birmingham
Research at Birmingham

Over-expression of DNMT3A predicts the risk of recurrent vulvar squamous cell carcinomas.

Leonard, Sarah; Pereira, Merlin; Fox, Richard; Yap, Jason; Gordon, Naheema; Luesley, David; Woodman, Ciaran; Kehoe, Sean; Ganesan, Raji

[Link to publication on Research at Birmingham portal](#)

1   **Title:** Over-expression of DNMT3A predicts the risk of recurrent vulvar squamous cell carcinomas

2   **Authors:** Sarah Leonard[1*], Merlin Pereira[1*], Richard Fox[2], Naheema Gordon[1], Jason Yap[1], Sean

3   Kehoe[1], David Luesley[1], Ciaran Woodman[1], Raji Ganesan[3]

4   *Both authors contributed equally to this work

5

6   [1]Institute of Cancer and Genomic Sciences, College of Dental and Medical School, University of

7   Birmingham, Edgbaston B15 2TT, United Kingdom.

8   [2]Cancer Research UK Clinical Trials Unit, University of Birmingham, Edgbaston B15 2TT, United

9   Kingdom.

10   [3]Birmingham Women's NHS Foundation Trust, Mindelsohn Way, Edgbaston, Birmingham, B15

11   2TG, United Kingdom.

12

13   **Corresponding author:** Dr Raji Ganesan. Mailing address: Birmingham Women's NHS Foundation

14   Trust,   Mindelsohn   Way,   Edgbaston,   Birmingham,   B15   2TG,   UK.   E-mail:

15   Raji.Ganesan@bwnft.nhs.uk

16

17   **Key words:** Vulvar cancer, DNA methylation, human papillomavirus (HPV), DNMT expression

18   cancer

19

22

23

24

25

26

27

28 **ABSTRACT**

29 Objective: Cancer initiation and progression has been linked to aberrant expression of the DNA

30 methyltransferases (DNMT), the enzymes which establish and maintain DNA methylation patterns

31 throughout the genome. In this study, we investigated if DNMT expression in vulvar squamous cell

32 carcinomas (VSCC) was related to clinical outcome.

33

34 Methods: DNMT1, DNMT3A and DNMT3B expression was measured in a subset of cases drawn

35 from a cohort of consecutive women treated for primary VSCC at the Pan Birmingham

36 Gynaecological Cancer Centre between 2001 and 2008. Univariable and multivariable competing risk

37 modelling was performed to identify whether DNMT expression was associated with local disease

38 recurrence or disease morbidity.

39

40 Results: Over-expression of DNMT3A in the invasive component of the tumour was seen in 44% of

41 tumours and was associated with an increased risk of local vulval recurrence (LVR) (HR = 4.51, p =

42 0.012). This risk was found to increase further after adjustment for disease stage (HR = 6.00, p =

43 0.003) and groin node metastasis (HR = 4.81, p = 0.008). Over-expression of DNMT3B was

44 associated with an increased risk of LVR (HR = 5.69 p = 0.03), however this ceased to be significant

45 after adjustment for groin node metastasis. In a subset analysis, over-expression of DNMT3A was

46 found to be significantly more common in VSCCs that stained negative for CDKN2A.

47

48 Conclusions: These observations are consistent with the possibility that epigenetic changes contribute

49 to vulval neoplasia and DNMT3A over-expression may be useful in predicting local disease

50 recurrence.

51

Introduction

Vulvar squamous cell carcinoma (VSCC) is relatively rare, accounting for approximately 5% of all gynecological malignancies and 95% of all vulvar malignancies [1]. However the incidence of VSCC has recently been rising, leading to increased clinical and scientific interest to improve therapeutic options [2-4]. Over the last two decades evidence has accumulated to show there are two different aetio-pathogenic pathways of the precursor lesions, termed vulvar intra-epithelial neoplasia (VIN) [5]. The first, usual type vulvar intraepithelial neoplasia (uVIN) is related to human papillomavirus (HPV) infection, predominantly type 16. The second pathway which is independent of HPV infection is referred to as differentiated VIN (dVIN) [6], and is often associated with Lichen Sclerosis (LS), a non-neoplastic, chronic inflammatory dermatosis with distinctive histology [7,8]. Although there is evidence to suggest that HPV-derived tumours confer a better survival over their HPV-independent counterpart in squamous cell cancer of the head and neck, such an advantage in survival is yet to be established in VSCC [9]. The rate of local vulval recurrence (LVR) has not changed over the last 3 decades and remained at around 25% despite the introduction of chemo-radiotherapy as an adjunct to surgery [10-12]. Our recent cohort study suggests that women with VSCC arising in the background of LS were more likely to develop LVR even when the primary tumours were completely excised with adequate excision margins [13].

DNA methylation is a covalent modification of DNA tightly regulated by a group of three enzymes known as the DNA methyltransferases (DNMT). In normal cells DNMT1 is primarily responsible for maintaining methylation; however its importance in maintaining cancer stem cells and driving tumorigenesis is also well established [14-16]. DNTM3A and DNMT3B are active *de novo* methyltransferases, although expressed at lower levels in adult somatic cells, they have been shown to be overexpressed and associated with adverse prognosis in several tumours including those of epithelial origin [17-19]. A recent study has shown that tumour suppressor gene (TSG) methylation in VSCC is associated with a poor disease prognosis however whether DNMT expression could be useful in determining disease prognosis remains unclear [20].

80   In this study, we compare for the first time, the expression of DNMT1, DNMT3A and DNMT3B in

81   the invasive component and in the normal adjacent epithelium of 66, 66 and 62 VSCC cases

82   respectively, and associated their expression with clinical data collected from patient's medical

83   records and CDKN2A status.

84

85   **Materials and methods**

86   Vulval tumour study population:

87   DNMT expression was examined in a subset of cases drawn from a cohort of 201 consecutive patients

88   first diagnosed with VSCC between 2000 and 2008. All patients were actively followed up for at least

89   5 years with cause of death assigned using information from multiple sources which included hospital

90   and hospice notes, general practitioner summaries, cancer registry records and information supplied

91   by the patient's family. Information on the following variables from case notes was documented: age,

92   smoking behaviour, multifocal disease, tumour differentiation, lymphovascular space involvement,

93   stage, groin node involvement and the presence of concomitant non-neoplastic epithelial disorders.

94   Information on local, regional and distant recurrences was also recorded during the follow-up period.

95   Tissue was obtained with written consent and the use of the biopsy material for research purposes had

96   been approved by the Birmingham, East, North and Solihull Research Ethics Committee (Reference

97   number 11/WM/0070).

98

99   Preparation of study material:

100   Paraffin embedded blocks were sectioned every 4μm and one section stained with haematoxylin and

101   eosin; sequential sections were used for routine immunohistochemical staining with the last of these

102   sections used for HPV DNA testing as described previously [13]. To avoid cross contamination, the

103   microtome blades were changed between cutting of each block. Tumour enriched tissue was macro

104   dissected and DNA was extracted using AllPrep DNA/RNA FFPE (formalin fixed paraffin

105   embedded) kit, according to manufacturer's instructions (Qiagen) and stored at -20°C.

106

107   Immunohistochemical analysis:

108   *DNMT immunohistochemistry*

109   Immunohistochemistry to examine the expression of DNMT1, DNMT3A and DNMT3B was

110   performed on 66, 66 and 62 VSCC cases respectively. We included only those cases which had

111   tumour and adjacent normal epithelium, and which performed similarly in two independent

112   experiments to control for batch variation; thus accounting for the number of cases used in this study.

113   Antigen expression was assessed using methods we have previously described [21].   Primary

114   antibodies to DNMT1 (ab19905 – ABCAM), DNMT3A (HPA026588-SIGMA) and DNMT3B

115   (HPA001595-SIGMA) were used at optimal working dilutions of 1:1200, 1:200, and 1:800

116   respectively. FFPE tissues from tonsil and skin were used as controls.

117   Two pathologists (RG, MP), independently reviewed the IHC stained slides. Distinctive brown DAB

118   nuclear staining was considered as positive for DNMT1, DNMT3A and DNMT3B protein expression.

119   All invasive vulvar cancer tissue sections were initially scanned at x4 objective to select the most

120   tumour dense area. Then one field at x10 objective was selected and the total number of DNMT

121   expressing tumour cells was assessed. When assessing keratinising sub-types of VSCC, it was noted

122   that the lack of nuclei in the keratin layer result in an apparent lack of staining. In such instances,

123   staining of nucleated layers was assessed.

124   *CDKN2A immunohistochemistry*

125   43 tumours which were stained for DNMT expression were also tested for CDKN2A expression. A

126   primary antibody to CDKN2A (clone E6H4 – CINtec) was used at an optimal working dilution of

127   1:25. Expression was considered positive when there was diffuse block staining of a segment of

128   epithelium. Patchy staining, even of strong intensity, or staining of varied intensity was considered

129   negative [22].

130   *H scoring*

131   The H-score scoring system was used to quantify the immunohistochemical staining. The score is

132   based on the proportion of target nuclei stained and the intensity of the stain [23]. The formula used

133   is: 3 x percentage of strongly stained nuclei (colour = brownish black) + 2 x percentage of moderately

134 stained nuclei (colour = brown) + 1 x percentage of weakly stained nuclei (colour = light brown) + 0 x

135 percentage of absent staining nuclei. Thus the H-score generated a range from 0 to 300, where 300 is

136 equivalent to 100% of the cells of interest exhibiting strong staining. DNMT were considered over-

137 expressed when the H score of the tumour was greater than that of the normal adjacent epithelium in

138 both replicates.

139

140 Statistical analysis:

141 Survival was summarised in each DNMT expression subgroup using the methods of Kaplan and

142 Meier. Univariate Cox models were used to quantify the association between cohort characteristics

143 and the risk of disease specific survival and time to local vulval recurrence, specifically the impact of

144 overexpression of DNMT markers. Multivariable Cox modelling was performed to adjust the

145 estimates of risk associated DNMT expression for known confounders. Given the limited size of each

146 cohort there was scope to adjust for just one confounder other than the DNMT descriptor in each

147 multivariable model. The patient characteristics were explored within each sub-cohort by DNMT

148 expression through comparison of proportions via a chi-squared test, and comparison medians using a

149 Wilcoxon rank-sum test. P values <0.05 were deemed statistically significant. Analyses were

150 performed in Stata V12.1

151

152 Pyrosequencing:

153 Genomic DNA (500 ng) was bisulfite converted using EZ DNA methylation kit (Zymo Research).

154 Pyrosequencing primers used for each of the promoter regions are shown in Supplemental table 1

155 The PCR was performed in a total volume of 50 μl using 25 μl HotStart Taq master mix (Thermo

156 Scientific) with 10pmol of primers and 10 μl of bisulfite-modified DNA. The pyrosequencing

157 reactions were performed on a Pyromark ID system (Qiagen) and analysed using Pyro Q-CpG

158 software (Qiagen).

159

160

161

162   **Results**

163   **Expression of DNMT1, DNMT3A and DNMT3B in VSCC**

164   DNMT1, DNMT3A and DNMT3B expression in the invasive component was compared to that in the

165   normal adjacent epithelium. Replicate cases which were not reproducible were removed from our

166   analysis. Therefore DNMT1, DNMT3A and DNMT3B expression in relation to prognosis was

167   analysed in 66, 55 and 45 VSCC cases respectively. DNMT1 was over-expressed in 83% (55/66) of

168   tumours, DNMT3A was over-expressed in 44% (24/55) and DNMT3B was over-expressed in 42%

169   (18/45) of tumours contributing to this analysis. For every case with DNMT over-expression, all

170   tumour cells stained positive in the invasive component. Representative examples of VSCC showing

171   over-expression of DNMT3A, DNMT3B and DNMT1 compared to the normal adjacent epithelium

172   (NAE) is shown in Figure 1.

173

174   **Risk of local vulval recurrence is associated with DNMT3A over-expression**

175   We set out to determine whether DNMT1, DNMT3A or DNMT3B over-expression is associated with

176   the risk of LVR.

177   *DNMT3A:* 13 of the 55 women in the DNMT3A cohort had a LVR. LVR free survival at 1, 3

178   and 5 years was found to be 75.4%, 56.3% and 47.5%, respectively, when DNMT3A was over-

179   expressed, and 96.4%, 92.6% and 83.3% when it was not (Figure 2A). In a univariable analysis,

180   DNMT3A over-expression was found to be associated with a 4.5 fold increased risk of LVR

181   (HR=4.51, p= 0.012). Risk of LVR was also increased in patients with groin node metastasis

182   (HR=4.72, p=0.005) (Table 1). In a multivariable analysis, DNMT3A over-expression continued to be

183   associated with increased risk of developing a LVR after adjustment for disease stage (HR=6.00,

184   p=0.003), groin node metastasis (HR=4.81, p=0.008), and the presence of LS adjacent to the primary

185   tumour (HR=4.08, p=0.019).

186

187   *DNMT3B:* 9 of the 45 women in the DNMT3B cohort had a LVR. LVR free survival at 1, 3 and 5

188   years was found to be 88.5%, 63.0% and 56.8%, respectively, when DNMT3B was over-expressed,

189 and 100%, 94.1% and 77.4% when it was not (Figure 2A). Like DNMT3A, univariable analysis

190 indicated that DNMT3B over-expression was associated with a significantly increased risk of LVR

191 (HR=5.69, p=0.03) (Table 1). Risk of LVR was also increased in women with groin node metastasis

192 (HR=4.07, p=0.04) and in those with tumours arising in a background of LS (HR=11.25, p=0.023)

193 (Table 1). In a multivariable analysis, DNMT3B over-expression continued to be associated with

194 increased risk of developing a LVR after adjustment for disease stage (HR=4.80, p=0.029). Unlike

195 DNMT3A, the excess risk associated with DNMT3B over-expression was attenuated and ceased to be

196 significant after adjustment for groin node metastasis (HR=4.18, p=0.088) and the presence of LS

197 adjacent to the primary tumour (HR=2.99, p=0.19)

198

199 *DNMT1:* 14 of the 66 women in the DNMT1 cohort had a LVR. LVR free survival at 1, 3 and 5 years

200 was found to be 91.2%, 81.3% and 75.0%, respectively, when DNMT1 was over-expressed and

201 90.0%, 90.0% and 64.3% when it was not (Figure 2A). Unlike DNMT3A and DNMT3B, univariable

202 analyses resulted in no evidence that DNMT1 over-expression increases risk of LVR (HR=0.77,

203 p=0.691) (Table 1). Risk of LVR was substantially increased in women with groin node metastasis

204 (HR=4.84, p=0.006) and in those with tumours arising in a background of LS (HR=4.41, p=0.012)

205 (Table 1). The risk of LVR associated with DNMT1 over-expression remained insignificant after

206 adjustment.

207

208 **DNMT3A, DNMT3B or DNMT1 expression does not influence disease specific mortality**

209 We next set out to determine whether DNMT1, DNMT3A or DNMT3B expression influences disease

210 mortality. However we found no significant difference in disease specific survival at 1, 3 and 5 years

211 for each of the DNMT (Figure 2B). In both univariable and multivariable analysis DNMT1,

212 DNMT3A and DNMT3B over-expression was not associated with increased mortality (Table 2).

213

214 **Over-expression of DNMT3A is associated with CDKN2A expression**

215 43 tumours from the VSCC cohort were tested for CDKN2A expression, which is indicative of HPV

216 induced dysplasia [22]. Of the 39 tumours for which CDKN2A result was available, 15 (38.5%)

217 showed positive block staining which is characteristic of a transforming HPV infection and 24 were

218 negative for CDKN2A expression (Figure 3A and B). When we compared CDKN2A and DNMT

219 expression, we found that in the 24 tumours negative for CDKN2A that over-expression of DNMT3A

220 was significantly more common (33.3% vs. 0%, $_{\text{difference in proportions}}$ 33.3%, 95% CI 2.34-56.25).

221 Representative examples showing CDKN2A expression in the absence of DNMT3A and vice versa

222 are shown in Figure 3. The expression of DNMT1 and DNMT3B did not vary significantly with

223 CDKN2A expression. We next examined the methylation status of the CDKN2A promoter using

224 pyrosequencing and found that CDKN2A negative tumours were significantly more methylated than

225 those tumours which were CDKN2A positive (T-test 0.0014) (Figure 4). Although the observations

226 in our results point to a relationship between DNMT3A over-expression and the absence of CDKN2A

227 expression, and a relationship between the absence of CDKN2A expression and hypermethylation of

228 the CDKN2A promoter, we were not able to directly link the over-expression of DNMT3A to

229 hypermethylation of the CDKN2A promoter. Although we show an association between DNMT3A

230 over expression and CDKN2A expression (indicative of HPV induced dysplasia), there was no

231 association between DNMT3A over-expression and HPV status when this was assigned using PCR

232 based assays.

233

234 **Discussion**

235 Approximately one in four women with VSCC will have a LVR within five years after primary

236 surgery [13]. Known risk factors for LVR are the clearance margin of the tumour, the depth of

237 invasion by tumour cells and, as we reported recently, the presence of LS adjacent to the tumour [24,

238 13]. However, more sophisticated predictors such as biomarkers capable of distinguishing cases likely

239 to recur, are of clinical importance.

240 Maintenance of DNA methylation by the DNMT is critical during development and in transcriptional

241 regulation; however aberrant expression of the DNMT has been reported for a number of human

242 cancers, including those of epithelial origin [16, 17, 19]. To date, expression of the DNMT in VSCC

243 has not been examined, therefore, we evaluated the expression of these enzymes and correlated our

244   results with CDKN2A staining, clinicopathologic parameters and survival data to determine the

245   prognostic significance of DNMT expression in vulvar cancer.

246

247   Our data showed that DNMT3A over-expression but not DNMT1 or DNMT3B was associated with a

248   significantly increased risk of LVR. This increased risk persisted after adjustment for groin node

249   metastasis suggesting that over-expression is an important predictor of VSCC recurrence. It has also

250   been shown for gastric carcinoma that DNMT3A over-expression while not DNMT3B or DNMT1 is

251   associated with poor disease survival [25]. For both epithelial tumours over-expression of DNMT3A

252   significantly contributes to disease recurrence or progression which may be associated with the

253   disruption of similar molecular pathways, such as epithelial-to-mesenchymal transition (EMT).

254   During EMT cells undergo a developmental switch from a polarized, epithelial phenotype to a highly

255   motile fibroblastoid or mesenchymal phenotype, a central process during cancer progression [26]. It is

256   recognised that VSCC with prominent fibromyxoid stroma have a poorer outcome. This stromal

257   response is phenotypic of epithelial mesenchymal transition [27]. Vulval cancers like other epithelial

258   malignancies, express a set of proteins which characterize strongly the transition from normal

259   epithelium to invasive VSCC [28]. The importance of DNMT3A in the regulation of these proteins

260   during EMT has recently been highlighted by Tan et al, where they show that a non-histone chromatin

261   protein, HMGA2 remodels chromatin to favour binding of DNMT3A to the *CDH1* promoter, thus

262   achieving sustained silencing of E-cadherin expression and promoting tumour cell invasion [29].

263   Our results also showed that DNMT3A overexpression was inversely related to the expression of

264   CDKN2A in these carcinomas. Expression of CDKN2A is related to the regulation of Rb by the viral

265   oncogene, E7. Following HPV integration into the host genome, E7 expression increases as does

266   CDKN2A expression due to its accumulation in the cell [30]. These results may tie in with a recent

267   finding published by Rodriguez et al, which suggests that HPV positive vulvar tumours may not

268   progress through EMT while HPV negative tumours do, again suggesting a role for DNMT3A in the

269   EMT process [28]. The presence of HPV when detected using PCR based methods did not reveal an

270   association with DNMT3A over expression, however this may not be surprising given that it may

271   only be transcriptionally active HPV that is related to disease progression [22].

272   Our results showed that over expression of DNMT3A and DNMT3B was associated with an LVR but

273   not survival. Identifying factors which are associated with local recurrence but not survival is not

274   unusual; in fact, these results are consistent with findings in our cohort study which shows that

275   mortality/survival is not influenced by LVR [13]. We also found in this study that women who

276   developed LVR also went on to develop at least one further episode of LVR within 2.3 years [13].

277   These findings might also suggest that DNMT3A is over expressed in a subset of less aggressive

278   tumours, a type associated with recurrence but not death. However given this is the first time we have

279   established this association, further work on the molecular biology of these VSCC tumours would be

280   necessary to fully understand this.

281   In summary, we have demonstrated that molecular profiling of the tumour and its adjacent epithelium

282   may be used to predict treatment outcomes in patients with VSCC. We have shown, for the first time

283   that DNMT3A over-expression is associated with tumours that do not contain transcriptionally active

284   HPV and have an increased risk of LVR. Our study suggests that DNMT3A may be used as a

285   surrogate marker for HPV-negative tumours and serve as a biomarker to identify those patients who

286   are at risk of developing LVR. Furthermore, given that a family of propiophenone derivatives have

287   recently been shown to be specific DNMT3A inhibitors in cancer cells, raises the interesting

288   possibility of testing these novel agents for their use in the prevention of some vulvar recurrences

289   [31]. This of course requires further evaluation including clinical studies.

290

291   **Conflict of interest**

292   The authors declare no conflict of interest.

293

294

295   **References**

296   1.   Cancer Research UK Cancer Statistics. Vulval cancer incidence statistics.

297   http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-

298   cancer-type/vulval-cancer/incidence.

299   2.   Akhtar-Danesh N, Elit L, Lytwyn A. Trends in incidence and survival of women with

300   invasive vulvar cancer in the United States and Canada: a population-based study.

301   Gynecol Oncol 2014;134(2):314-8.

302   3.   Judson PL, Habermann EB, Baxter NN, Durham SB, Virnig BA. Trends in the incidence

303   of invasive and in situ vulvar carcinoma. Obstet Gynecol 2006;107(5):1018-22.

304   4.   Deckers-Figiel S, Hampl JA, Rein D, Bender HG. New aspects of vulvar cancer: changes

305   in localization and age of onset. Gynecol Oncol 2008;109(3):340–45.

306   5.   Del Pino M, Rodriguez-Carunchio L, Ordi J. Pathways of vulvar intraepithelial neoplasia

307   and squamous cell carcinoma. Histopathology 2013;62(1):161–75.

308   6.   Preti M, Igidbashian S, Costa S, Cristoforoni P, Mariani L, Origoni M, et al. VIN usual

309   type-from the past to the future. Ecancermedicalscience 2015;29(9):531.

310   7.   Sideri M, Jones RW, Wilkinson EJ, Preti M, Heller DS, Scurry J, et al. Squamous vulvar

311   intraepithelial neoplasia: 2004 modified terminology, ISSVD Vulvar Oncology

312   Subcommittee. J Reprod Med 2005;50(11):807-10.

313   8.   van de Nieuwenhof HP, Bulten J, Hollema H, Dommerholt RG, Massuger LF, van der

314   Zee AG *et al*. Differentiated vulvar intraepithelial neoplasia is often found in lesions,

315   previously diagnosed as lichen sclerosus, which have progressed to vulvar squamous cell

316   carcinoma. Mod. Pathol 2011;24(2):297–305.

317   9.   Iyer NG, Dogan S, Palmer F, Rahmati R, Nixon IJ, Lee N, et al. Detailed Analysis of

318   Clinicopathologic Factors Demonstrate Distinct Difference in Outcome and Prognostic

319   Factors Between Surgically Treated HPV-Positive and Negative Oropharyngeal Cancer.

320   Ann Surg Oncol 2015;22(13):4411-21.

321   10.   Gadducci A, Tana R, Barsotti C, Guerrieri ME, Genazzani AR. Clinico-pathological and

322   biological prognostic variables in squamous cell carcinoma of the vulva. Crit Rev Oncol

323   Hematol 2012;83(1):71–83.

324   11.   Coulter J, Gleeson N. Local and regional recurrence of vulval cancer: management

325   dilemmas. Best Pract Res Clin Obstet Gynaecol 2003;17(4):663–81.

326   12.   Mahner S, Jueckstock J, Hilpert F, Neuser P, Harter P, de Gregorio N, et al. Adjuvant

327   therapy in lymph node-positive vulvar cancer: the AGO-CaRE-1 study. J Natl Cancer Inst

328   2015;107(3).

329   13.   Yap JK, Fox R, Leonard S, Ganesan R, Kehoe ST, Dawson CW, et al. Adjacent Lichen

330   Sclerosis predicts local recurrence and second field tumour in women with vulvar

331   squamous cell carcinoma. Gynecol Oncol 2016:Jul 7: Epub ahead of print.

332   14.   Saito Y, Kanai Y, Nakagawa T, Sakamoto M, Saito H, Ishii H, et al. Increased protein

333   expression of DNA methyltransferase (DNMT) 1 is significantly correlated with the

334   malignant potential and poor prognosis of human hepatocellular carcinomas. Int J Cancer

335   2003;105(4):527–32.

336   15.   Leonard SM, Wei W, Collins SI, Pereira M, Diyaf A, Constandinou-Williams C, et al.

337   Oncogenic human papillomavirus imposes an instructive pattern of DNA methylation

338   changes which parallel the natural history of cervical HPV infection in young women.

339   Carcinogenesis 2012;33(7):1286-93.

340   16.   Pathania R, Ramachandran S, Elangovan S, Padia R, Yang P, Cinghu S, et al. DNMT1 is

341   essential for mammary and cancer stem cell maintenance and tumorigenesis. Nat

342   Commun. 2015: 24;6:6910.

343   17.   el-Deiry WS, Nelkin BD, Celano P, Yen RW, Falco JP, Hamilton SR, et al. High

344   expression of the DNA methyltransferase gene characterizes human neoplastic cells and

345   progression stages of colon cancer. Proc Natl Acad Sci USA 1991;88(8):3470–4.

346   18.   Li M, Wang Y, Song Y, Bu R, Yin B, Fei X et al. Expression profiling and

347   clinicopathological significance of DNA methyltransferase 1, 3A and 3B in sporadic

348   human renal cell carcinoma. Int J Clin Exp Pathol 2014;7(11):7597-609.

13

349   19.   Zhang JJ, Zhu Y, Zhu Y, Wu JL, Liang WB, et al. Association of increased DNA
350   methyltransferase expression with carcinogenesis and poor prognosis in pancreatic ductal
351   adenocarcinoma. Clin Transl Oncol 2012;14(2): 116–24.

352   20.   Guerrero D, Guarch R, Ojer A, Casas JM, Mendez-Meca C, Esteller M. et al. Differential
353   hypermethylation of genes in vulvar cancer and lichen sclerosus coexisting or not with
354   vulvar cancer. Int J Cancer 2011;128(12) 2853–64.

355   21.   Leonard S, Gordon N, Smith N, Rowe M, Murray PG, Woodman CB. Arginine
356   Methyltransferases Are Regulated by Epstein-Barr Virus in B Cells and Are Differentially
357   Expressed in Hodgkin's Lymphoma. Pathogens 2012;1(1):52-64.

358   22.   Leonard SM, Pereira M, Roberts S, Cuschieri K, Nuovo G, Athavale R, et al. Evidence of
359   disrupted high-risk human papillomavirus DNA in morphologically normal cervices of
360   older women. Sci Rep 2016; 15(6):20847.

361   23.   Thike AA, Chng MJ, Fook-Chong S, Tan PH. Immunohistochemical expression of
362   hormone receptors in invasive breast carcinoma: correlation of results of H-score with
363   pathological parameters. Pathology 2001;33(1):21–5.

364   24.   Rouzier R, Haddad B, Plantier F, Dubois P, Pelisse M, Paniel BJ. Local relapse in
365   patients treated for squamous cell vulvar carcinoma: incidence and prognostic value.
366   Obstet Gynecol 2002;100(6):1159-67.

367   25.   Cao XY, Ma HX, Shang YH, Jin MS, Kong F, Jia ZF, et al .DNA methyltransferase3a
368   expression is an independent poor prognostic indicator in gastric cancer. World J
369   Gastroenterol 2014;20(25):8201-8.

370   26.   Zhou X, Zhang H, Han X. Role of epithelial to mesenchymal transition proteins in
371   gynecological cancers: pathological and therapeutic perspectives. Tumor Biol
372   2014;35:9523–30.

373   27.   Ambros RA, Malfetano JH, Mihm MC. Clinicopathologic features of vulvar squamous
374   cell carcinomas exhibiting prominent fibromyxoid stromal response. Int J Gynecol Pathol
375   1996;15(2):137-45.

376   28.   Rodrigues IS, Lavorato-Rocha AM, de M Maia B, Stiepcich MM, de Carvalho FM,

377   Baiocchi G, et al. Epithelial-mesenchymal transition-like events in vulvar cancer and its

378   relation with HPV. Br J Cancer 2013;109(1):184-94.

379   29.   Tan EJ, Kahata K, Idås O, Thuault S, Heldin CH, Moustakas A. The high mobility group

380   A2 protein epigenetically silences the Cdh1 gene during epithelial-to-mesenchymal

381   transition. Nucleic Acids Res 2015;43(1):162-78.

382   30.   Tringler B, Grimm C, Dudek G, Zeillinger R, Tempfer C, Speiser P, et al. p16INK4a

383   expression in invasive vulvar squamous cell carcinoma. Appl Immunohistochem Mol

384   Morphol 2007;15(3):279-83.

385   31.   Erdmann A, Menon Y, Gros C, Molinier N, Novosad N, Samson A, et al. Design and

386   synthesis of new non nucleoside inhibitors of DNMT3A. Bioorg Med Chem

387   2015;23(17):5946-53.

388

389

390

391   **Figure and Table Legends**

392   Figure 1: Examples of VSCC with over-expression of DNMT1, DNMT3A or DNMT3B. The H score

393   of the invasive areas of the tumour was compared with that of the non-neoplastic squamous

394   epithelium lying adjacent to the invasive lesion (NAE).

395

396   Figure 2A: Univariate analysis showing a statistically significant increased risk of local vulval

397   recurrence when there is over-expression of DNMT3A and DNMT3B but not DNMT1. 2B:

398   Univariate analysis showing a statistically insignificant risk of disease specific survival (i.e. VSCC

399   related death) when there is over-expression of DNMT3A, DNMT3B and DNMT1.

400

401   Figure 3: Low level DNMT3A expression in tumours with CDKN2A overexpression. A

402   representative example of a tumour in which both the immature keratinising and keratinising

403   components of the tumour show strong CDKN2A expression but low level DNMT3A expression.

404

405   Figure 4: Graph showing the average methylation of the P16 promoter in 43 VSCC tumours.

406

407

408   Table 1: Univariable analysis showing the risk of Local Vulval Recurrence in relation to DNMT

409   expression and patient and disease related prognostic factors.

410

411   Table 2: Univariable analysis showing the risk of death from VSCC in relation to DNMT over-

412   expression and patient and disease related prognostic factors.

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

Covariate		DNMT 1 (N=66)		DNMT3A (N=55)		DNMT3B (N=45)	
		HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	P-value
DNMT over-expression	Not over-expressed	1 (reference)		1 (reference)		1 (reference)	
	Over-expressed	0.77 (0.21, 2.77)	0.691	**4.51 (1.40, 14.49)**	**0.012**	**5.69 (1.17, 27.57)**	**0.031**
Age	≤70	1 (reference)		1 (reference)		1 (reference)	
	>70	1.16 (0.40, 3.36)	0.781	0.73 (0.25, 2.11)	0.563	0.55 (0.14, 2.21)	0.400
Smoking status	Smoker/Ex-Smoker	1 (reference)		1 (reference)		1 (reference)	
	No	7.42 (0.96, 57.32)	0.055	3.76 (0.83, 17.06)	0.086	3.28 (0.40, 26.81)	0.269
	Not mentioned	1.88 (0.12, 30.10)	0.657	0.57 (0.05, 6.25)	0.642	1.06 (0.07, 16.99)	0.968
Stage if disease	1/2	1 (reference)		1 (reference)		1 (reference)	
	3/4	2.8 (0.95, 8.25)	0.062	3.34 (1.14, 9.77)	0.028	1.69 (0.15, 33.35)	0.437
Tumour size	≤4cm	1 (reference)		1 (reference)		1 (reference)	
	> 4cm	1.16 (0.39, 3.46)	0.789	1.07 (0.36, 3.18)	0.909	0.98 (0.45, 6.35)	0.990
Multifocal disease	No	1 (reference)		1 (reference)		1 (reference)	
	Yes	1.37 (0.43, 4.39)	0.593	1.71 (0.54, 5.47)	0.363	1.04 (0.22, 5.04)	0.96
Groin node involvement	No	1 (reference)		1 (reference)		1 (reference)	
	Yes	**4.84 (1.56, 15.07)**	**0.006**	**4.72 (1.60, 13.93)**	**0.005**	**4.07 (1.06, 15.59)**	**0.04**
Lymphovascular space involvement	No	1 (reference)		1 (reference)		1 (reference)	
	Unavailable	1.78 (0.48, 6.60)	0.388	2.20 (0.55, 8.79)	0.266	0.00 (0.00, .)	1
	Yes	0.37 (0.08, 1.73)	0.209	1.20 (0.37, 3.95)	0.76	0.63 (0.16, 2.53)	0.514
Excision margin status	Optimum	1 (reference)		1 (reference)		1 (reference)	
	Incomplete	0.00 (0.00, .)	1	0.00 (0.00, .)	1	0.00 (0.00, .)	1
	Sub-optimum	0.85 (0.26, 2.76)	0.786	0.72 (0.22, 2.33)	0.58	0.82 (0.20, 3.30)	0.781
	Unavailable	4.05 (0.49, 33.68)	0.196	3.45 (0.41, 28.78)	0.253	1.00 (., .)	.
Tumour differentiation	Well	1 (reference)		1 (reference)		1 (reference)	
	Moderate	1.56 (0.41, 5.83)	0.512	1.24 (0.33, 4.61)	0.751	1.09 (0.22, 5.44)	0.917
	Poorly	0.93 (0.22, 3.91)	0.924	0.87 (0.23, 3.26)	0.84	0.49 (0.08, 2.96)	0.438
	Not graded	1.93 (0.37, 9.98)	0.431	0.00 (0.00, .)	1	0.76 (0.08, 7.40)	0.816
LS+/-VIN	No LS	1 (reference)		1 (reference)		1 (reference)	
	LS, +/- Vin	**4.41 (1.38, 14.07)**	**0.012**	2.47 (0.83, 7.36)	0.106	**11.25 (1.40, 90.14)**	**0.023**

Table 1

17

Covariate		DNMT1 (N=66)		DNMT3A (N=55)		DNMT3B (N=45)	
		HR (95% CI)	P-value	HR (95% CI)	P-value	HR (95% CI)	P-value
DNMT over-expression	No	1 (reference)		1 (reference)		1 (reference)	
	Yes	0.85 (0.28, 2.56)	0.772	2.02 (0.66, 6.21)	0.219	1.48 (0.45, 4.86)	0.517
Age	≤70	1 (reference)		1 (reference)		1 (reference)	
	>70	1.34 (0.53, 3.42)	0.535	2.35(0.71, 7.77)	0.162	0.82 (0.25, 2.69)	0.740
Smoking status	Smoker/Ex-Smoker	1 (reference)		1 (reference)		1 (reference)	
	Never smoker	1.24 (0.39, 3.94)	0.721	1.08 (0.27, 4.33)	0.917	0.57 (0.13, 2.57)	0.466
	Not mentioned	2.26 (0.60, 8.57)	0.23	1.91 (0.42, 8.77)	0.403	1.25 (0.28, 5.63)	0.775
Stage of disease	1/2	1 (reference)		1 (reference)		1 (reference)	
	3/4	9.95 (3.26, 30.43)	0.000	6.27 (1.71, 22.98)	0.006	6.94 (1.49, 32.3)	0.014
Tumour size	≤4cm	1 (reference)		1 (reference)		1 (reference)	
	>4cm	3.63 (1.28, 10.26)	0.015	4.86 (1.25, 18.87)	0.022	1.92 (0.54, 6.83)	0.312
Multifocal disease	No	1 (reference)		1 (reference)		1 (reference)	
	Yes	0.69 (0.20, 2.37)	0.551	0.80 (0.18, 3.61)	0.77	0.89 (0.19, 4.15)	0.884
Groin node involvement	No	1 (reference)		1 (reference)		1 (reference)	
	Yes	9.68 (3.51, 26.66)	<0.01	6.16 (1.87, 20.31)	0.003	6.50 (1.66, 25.5)	0.007
Lymphovascular space involvement	No	1 (reference)		1 (reference)		1 (reference)	
	Yes	1.30 (0.48, 3.49)	0.607	2.07 (0.58, 7.33)	0.261	1.79 (0.52, 6.17)	0.356
	Unavailable	1.66 (0.45, 6.17)	0.446	2.61 (0.57, 11.87)	0.214	0.00 (0.00, .)	1
Excision margin status	Optimum	1 (reference)		1 (reference)		1 (reference)	
	Incomplete	3.92 (1.00, 15.29)	0.049	7.82 (0.83, 73.32)	0.072	3.76 (0.41, 34.8)	0.243
	Sub-optimum	1.84 (0.60, 5.64)	0.289	2.79 (0.77, 10.07)	0.118	1.52 (0.38, 6.13)	0.554
	Unavailable	7.96 (1.98, 31.95)	0.003	10.73 (1.82, 63.33)	0.009	1.3e+18 (., .)	.
Tumour differentiation	Well	1 (reference)		1 (reference)		1 (reference)	
	Moderate	1.89 (0.53, 6.72)	0.326	1.27 (0.34, 4.80)	0.724	1.29 (0.29, 5.85)	0.738
	Poorly	2.90 (0.95, 8.89)	0.062	0.85 (0.21, 3.45)	0.818	1.13 (0.25, 5.07)	0.87
	Not graded	0.00 (0.00, .)	1	0.00 (0.00, .)	1	0.00 (0.00, .)	1
LS+/-VIN	No LS	1 (reference)		1 (reference)		1 (reference)	
	LS, +/- Vin	1.41 (0.57, 3.47)	0.458	0.92 (0.30, 2.82)	0.887	3.22 (0.85, 12.1)	0.084

Table 2